EUCTR2016-000945-29-IT进行中(未招募)1 期
Activity of Abiraterone Acetate in the management of Cushing’s syndrome in patients with adrenocortical carcinoma (ABACUS) - ABACUS
AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA0 个研究点目标入组 30 人开始时间: 2020年11月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically-confirmed diagnosis of ACC
- •CT or MRI evidence of metastatic or locally advanced ACC (ENSAT stage III-IV) unsuitable for radical surgery
- •Age = 18 years
- •Confirmed diagnosis of Cushing’s syndrome validated by:
- •-two 24 h urinary collections for UFC at least 1.5 times the upper the normal levels, within 2 weeks prior to enrollment;
- •-serum ACTH levels lower than the normal range;
- •ECOG performance status = 2
- •Effective contraception
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •Life expectancy less than 3 months
- •Liver disease, such as cirrhosis, chronic or persistent active hepatitis or AST/ALT > 2 x ULN, bilirubin >2 x ULN
- •Heart failure (NYHA class III or IV), unstable angina, severe arrhythmia or clinically significant impairment of heart function
- •Major surgical procedure within one month prior entering the study
- •Renal impairment (creatinine clearance < 40 ml/min).
- •WBC <3 x 109 /L; Hb <13 g/dL for men and <12 g/dL for women; platelets <100 x 109 /L
- •Any other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
- •Pregnant or breast-feeding women
- •History of alcohol or drug abuse
- •History of recent or active prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, or other treated malignancies with no evidence of disease for at least three years)
- •Acute or chronic uncontrolled infections
- •Patient non-compliance
研究者
相似试验
尚未招募
2 期
Comparison of therapeutic efficacy between two different treatment methods in patients with prostate cancerCTRI/2018/07/014703All India Institute of Medical Sciences
尚未招募
不适用
The phaseII study of the efficacy of Abirateron acetate and Dutasteride therapy for castration resistant prostate cancer.castration resistant prostate cancerJPRN-UMIN000027795Department od Urology, Yamaguchi Graduate School of Medicine20
进行中(未招募)
1 期
A study of Abiraterone Acetate in Subjects with Advanced Metatstatic Prostate Cancer Who Have Progressed After ChemotherapyMetastatic Castration-Resistant Prostate Cancer (PCR)MedDRA version: 14.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021425-13-GRJanssen-Cilag International NV2,316
进行中(未招募)
1 期
An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based ChemotherapyMetastatic Castration-Resistant Prostate Cancer (PCR)MedDRA version: 14.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021425-13-CZJanssen-Cilag International NV5,000
进行中(未招募)
1 期
A study of Abiraterone Acetate in Subjects with Advanced Metatstatic Prostate Cancer Who Have Progressed After ChemotherapyMetastatic Castration-Resistant Prostate Cancer (PCR)MedDRA version: 16.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021425-13-DKJanssen-Cilag International NV5,000
